Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study
Authors' conclusion
Semaglutide treatment resulted in significant reduction in weight and BMI in patients with obesity undergoing dialysis, while maintaining an acceptable side effect profile comparable to that of the non-dialysis population.
Study context
- Population
- Patients with body mass index (BMI) ≥ 30.00 kg/m² undergoing dialysis (12 haemodialysis, 1 peritoneal dialysis), not listed for transplantation due to weight; mean age 64.0 ± 6.4 years, mean BMI 37.3 ± 3.9 kg/m²
- Participants
- 13 patients
- Outcome
- Change in body weight and BMI (repeated measures ANOVA)
- Follow-up
- 12 weeks
Methodological detailssingle-arm, 12-week
- Single-arm
- 12-week
Main finding
As reported in the abstract
Weight reduction · week 12
| Group | Value | Range |
|---|---|---|
| Semaglutide | average 4.6 (SD 2.4) kg | 2.0 to 9.7 kg |
Semaglutide
Valueaverage 4.6 (SD 2.4) kg
Range2.0 to 9.7 kg
- Weight and BMI reduction across the study period
- P < 0.001
Observational data: associations, not effects.
Further findings
Reconsideration of transplant listing · ≈9 months after treatment start
- Patients able to seriously reconsider being listed for transplantation
- 3
Safety
Side effects and discontinuation
- Discontinued due to nausea/vomiting
- 1
- Died of unrelated causes
- 2
- Reported side effects
- 6
Original publication
Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study. Diabetes Obes Metab. Published 7 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →